Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
TORONTO and EDMONTON, Alberta, Feb. 26, 2024 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna Zentaris”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce today that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) recommended that both companies’ securityholders vote FOR the all-stock merger of equals transaction (the “Transaction”) pursuant to the terms announced on December 14, 2023.
Related news for (CRPOF)
- Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
- Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings